Literature DB >> 2409211

Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.

T Kinoshita, M E Medof, R Silber, V Nussenzweig.   

Abstract

Decay-accelerating factor (DAF) is a 70,000 Mr protein that has been isolated from the membrane of red cells. The function of DAF is to inhibit the assembly of amplifying enzymes of the complement cascade on the cell surface, thereby protecting them from damage by autologous complement. We raised monoclonal antibodies to DAF and used them to study its distribution in cells from the peripheral blood of normal individuals and of patients with paroxysmal nocturnal hemoglobinuria (PNH), a disease characterized by the unusual susceptibility of red cells to the hemolytic activity of complement. The results of immunoradiometric assays and of fluorescence-activated cell sorter analysis showed that DAF was present not only on red cells but was widely distributed on the surface membrane of platelets, neutrophils, monocytes, and B and T lymphocytes. By Western blotting, we observed small but consistent differences in the Mr of DAF from the membranes of various cell types. Quantitative studies showed that phagocytes and B lymphocytes, which presumably enter more frequently in contact with immune complexes and other potential activators of complement, had the highest DAF levels. As previously reported by others, the red cells from PNH patients were DAF deficient. When the patients' red cells were incubated in acidified serum (Ham test), only the DAF-deficient cells were lysed. In addition, we detected defects in DAF expression on platelets and all types of leukocytes. The observed patterns of DAF deficiency in these patients were consistent with the concept that the PNH cells were of monoclonal origin. In one patient, abnormal and normal cells were found only in the erythroid, myeloid, and megakaryocytic lineages. In two other patients, the lymphocytes were also DAF deficient, suggesting that a mutation occurred in a totipotent stem cell. It appears, therefore, that the lesion leading to PNH can occur at various stages in the differentiation of hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2409211      PMCID: PMC2187705          DOI: 10.1084/jem.162.1.75

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  35 in total

Review 1.  Paroxysmal nocturnal haemoglobinuria.

Authors:  G Sirchia; S M Lewis
Journal:  Clin Haematol       Date:  1975-02

2.  Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes.

Authors:  M S Weiner; C Bianco; V Nussenzweig
Journal:  Blood       Date:  1973-12       Impact factor: 22.113

3.  Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells.

Authors:  S B Oni; B O Osunkoya; L Luzzatto
Journal:  Blood       Date:  1970-08       Impact factor: 22.113

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.

Authors:  E M Hoffmann
Journal:  Immunochemistry       Date:  1969-05

6.  Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.

Authors:  E M Hoffman
Journal:  Immunochemistry       Date:  1969-05

7.  A platelet and granulocyte membrane defect in paroxysmal nocturnal hemoglobinuria: usefulness for the detection of platelet antibodies.

Authors:  R H Aster; S E Enright
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

8.  Normal human lymphocytes treated in vitro with the sulfhydryl compound AET: relationship to the lymphocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  G Sirchia; S Ferrone
Journal:  Blood       Date:  1971-05       Impact factor: 22.113

9.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

10.  Cytological evidence for a relationship between normal hemotopoietic colony-forming cells and cells of the lymphoid system.

Authors:  A M Wu; J E Till; L Siminovitch; E A McCulloch
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  101 in total

1.  Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

2.  Expression and localization of proteins of the complement system in human skin.

Authors:  N Dovezenski; R Billetta; I Gigli
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

3.  Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses.

Authors:  Lisa A Mannik; Ian Chin-Yee; Shayan Sharif; Luc Van Kaer; Terry L Delovitch; S M Mansour Haeryfar
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

4.  Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

Authors:  Rachael Watson; Emma Wearmouth; Amy-Claire McLoughlin; Arthur Jackson; Sophie Ward; Paula Bertram; Karim Bennaceur; Catriona E Barker; Isabel Y Pappworth; David Kavanagh; Susan M Lea; John P Atkinson; Timothy H J Goodship; Kevin J Marchbank
Journal:  Mol Immunol       Date:  2014-08-21       Impact factor: 4.407

Review 5.  Multifaceted role of glycosylation in transfusion medicine, platelets, and red blood cells.

Authors:  Melissa M Lee-Sundlov; Sean R Stowell; Karin M Hoffmeister
Journal:  J Thromb Haemost       Date:  2020-05-28       Impact factor: 5.824

6.  Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.

Authors:  S Chen; T Caragine; N K Cheung; S Tomlinson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

7.  Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.

Authors:  D M Lublin; E S Thompson; A M Green; C Levene; M J Telen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 8.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

9.  Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.

Authors:  S Varsano; L Rashkovsky; H Shapiro; D Ophir; T Mark-Bentankur
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

10.  Role of complement activation in obliterative bronchiolitis post-lung transplantation.

Authors:  Hidemi Suzuki; Mark E Lasbury; Lin Fan; Ragini Vittal; Elizabeth A Mickler; Heather L Benson; Rebecca Shilling; Qiang Wu; Daniel J Weber; Sarah R Wagner; Melissa Lasaro; Denise Devore; Yi Wang; George E Sandusky; Kelsey Lipking; Pankita Pandya; John Reynolds; Robert Love; Thomas Wozniak; Hongmei Gu; Krista M Brown; David S Wilkes
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.